IBD item numbers

PBS item numbers and streamlined authority codes for biologics and small molecules in ulcerative colitis and Crohn's disease. Select a number to copy it.

From the ulcerative colitis code sheet (December 2025) and the Crohn's disease code sheets (November 2025). Item numbers change, so check the PBS Schedule if in doubt.

Moderate to severe ulcerative colitis

Ulcerative colitis code sheet, December 2025

Adalimumab Humira, Amgevita, Abrilada, Hadlima, Hyrimoz, Yuflyma

Item	Formulation	Qty	Rpts
Induction (initial, change or recommencement)Online or written
	adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima	6 (3 packs of 2) or 2 (patient under 40 kg)	0
	adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima	6 (3 packs of 2) or 2 (patient under 40 kg)	0
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	6 (3 packs of 2) or 2 (patient under 40 kg)	0
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	6 (3 packs of 2) or 2 (patient under 40 kg)	0
	adalimumab 80mg/0.8mL syringeHumira, Yuflyma, Hyrimoz (pen only)	3 or 1 (patient under 40 kg)	0
	adalimumab 80mg/0.8mL penHumira, Yuflyma, Hyrimoz (pen only)	3 or 1 (patient under 40 kg)	0
Balance, patient under 40 kg (20mg)Online or telephone
	adalimumab 20mg/0.2mL syringeHumira	2	3
	adalimumab 20mg/0.4mL syringeAmgevita	2	3
	adalimumab 20mg/0.4mL syringeAbrilada	2	3
Balance, patient 40 kg or more (40mg)Online or telephone
	adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima	2	2
	adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima	2	2
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	2	2
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	2	2
First continuing and balanceOnline or telephone
	adalimumab 20mg/0.2mL syringeHumira	2 (20mg/fortnight) or 4 (20mg/week)	5
	adalimumab 20mg/0.4mL syringeAmgevita	2 (20mg/fortnight) or 4 (20mg/week)	5
	adalimumab 20mg/0.4mL syringeAbrilada	2 (20mg/fortnight) or 4 (20mg/week)	5
	adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima	2 (40mg/fortnight) or 4 (40mg/week)	5
	adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima	2 (40mg/fortnight) or 4 (40mg/week)	5
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week)	5
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week)	5
Subsequent continuingStreamlined authority
	adalimumab 20mg/0.2mL syringeHumira	2 (20mg/fortnight) or 4 (20mg/week)	5
	adalimumab 20mg/0.4mL syringeAmgevita	2 (20mg/fortnight) or 4 (20mg/week)	5
	adalimumab 20mg/0.4mL syringeAbrilada	2 (20mg/fortnight) or 4 (20mg/week)	5
	adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima	2 (40mg/fortnight) or 4 (40mg/week)	5
	adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima	2 (40mg/fortnight) or 4 (40mg/week)	5
	adalimumab 40mg/0.4mL syringeHadlima, Yuflyma, Humira, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week)	5
	adalimumab 40mg/0.4mL penHadlima, Yuflyma, Humira, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week)	5

Golimumab Simponi

Item	Formulation	Qty	Rpts
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	golimumab 100mg/mL injection, pen	3	0
	golimumab 100mg/mL injection, pen	1	1
Continuing and balanceOnline or telephone
	golimumab 100mg/mL injection, pen	1	5

Tofacitinib Xeljanz

Section 85

Item	Formulation	Qty	Rpts
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	tofacitinib 10mg tabs	56	3
	tofacitinib 5mg tabs	56	3
Continuing and balanceOnline or telephone
	tofacitinib 10mg tabs	56	5
	tofacitinib 5mg tabs	56	5

Ozanimod Zeposia

Section 85

Item	Formulation	Qty	Rpts
Dose escalation at initial or re-initiation (titration pack)Streamlined authority
	ozanimod 230mcg caps [4] + 460mcg caps [3]	1 (pack)	0
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	ozanimod 920mcg caps	28	3
Continuing and balanceOnline or telephone
	ozanimod 920mcg caps	28	5

Upadacitinib Rinvoq

Section 85

Item	Formulation	Qty	Rpts
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	upadacitinib 45mg tabs	28	3
Continuing and balanceOnline or telephone
	upadacitinib 15mg tabs	28	5
	upadacitinib 30mg tabs	28	5
Dose modificationOnline or telephone
	upadacitinib 15mg tabs	28	1
	upadacitinib 30mg tabs	28	1

Etrasimod Velsipity

Section 85

Item	Formulation	Qty	Rpts
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	etrasimod 2mg tabs	28	3
Continuing and balanceOnline or telephone
	etrasimod 2mg tabs	28	5

Vedolizumab IV Entyvio IV

Section 100

Item	Formulation	Qty	Rpts
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	PUBLIC vedolizumab 300mg vial	1	2
	PRIVATE vedolizumab 300mg vial	1	2
Continuing and balanceOnline or telephone
	PUBLIC vedolizumab 300mg vial	1	2
	PRIVATE vedolizumab 300mg vial	1	2

Vedolizumab subcutaneous Entyvio SC

Section 85

Item	Formulation	Qty	Rpts
Initial treatment after 3 doses of IVOnline or written
	vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen	2	0
Initial treatment after 2 doses of IVOnline or written
	vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen	2	2
Continuing or switching to subcutaneousOnline or telephone
	vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen	2	5
Balance of supply: replacements, lost or top-upsOnline or telephone
	vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen	2	X

Ustekinumab IV Stelara IV, Steqeyma IV

Section 100

Item	Formulation	Qty	Rpts
Loading (initial, change, recommencement or balance)Online or written
	PUBLIC ustekinumab 130mg vial	4	0
	PRIVATE ustekinumab 130mg vial	4	0

Ustekinumab subcutaneous Stelara SC, Steqeyma SC

Section 85

Item	Formulation	Qty	Rpts
BalanceOnline or written
	ustekinumab 90mg syringe	1	0
First and subsequent continuing, and balanceOnline or telephone
	ustekinumab 90mg syringe	1	1 (90mg/12wks) or 2 (90mg/8wks)
Subsequent continuing for biosimilarsStreamlined authority
	ustekinumab 90mg syringeSteqeyma	1	1

Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis

Section 100

Item	Formulation	Qty	Rpts
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
Continuing (all brands)Online or telephone
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
Continuing for biosimilarsStreamlined authority
	PUBLIC infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima	up to 5	2
	PRIVATE infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima	up to 5	2

Infliximab subcutaneous Remsima

Section 85. For patients 18 years and over only.

Item	Formulation	Qty	Rpts
Initial or change (with 2 IV doses) or recommencement (with 1 IV dose)Online or written
	infliximab 120mg/mL syringe, subcutaneous	2	2
	infliximab 120mg/mL pen, subcutaneous	2	2
Balance of supply, initialOnline or telephone
	infliximab 120mg/mL syringe, subcutaneous	2	X
	infliximab 120mg/mL pen, subcutaneous	2	X
Continuing, or switching from IV to subcutaneousStreamlined authority
	infliximab 120mg/mL syringe, subcutaneous	2	5
	infliximab 120mg/mL pen, subcutaneous	2	5

Acute severe ulcerative colitis

Ulcerative colitis code sheet, December 2025

Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis

Section 100

Item	Formulation	Qty	Rpts
First dose as a hospital inpatient, remaining 2 doses streamlinedIncrease quantity: telephone
	PUBLIC infliximab 100mg vials	X*	1
	PRIVATE infliximab 100mg vials	X*	1

Adult Crohn's disease

Crohn's disease code sheet (adult), November 2025

Adalimumab Humira, Abrilada, Amgevita, Hadlima, Hyrimoz, Yuflyma

Section 85

Item	Formulation	Qty	Rpts
Loading (initial, change or recommencement)Online or written
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 80mg/0.8mL syringeHumira, Yuflyma, Hyrimoz (pen only)	3	0
	adalimumab 80mg/0.8mL penHumira, Yuflyma, Hyrimoz (pen only)	3	0
Balance (initial and continuing)Online or telephone
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	2	2
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	2	2
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	2	2
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	2	2
First and subsequent continuingOnline or written
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight)	5
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight)	5
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight)	5
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight)	5
Subsequent continuing for biosimilarsStreamlined authority
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	2	5
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	2	5
	adalimumab 40mg/0.4mL syringeHadlima, Yuflyma, Hyrimoz	2	5
	adalimumab 40mg/0.4mL penHadlima, Yuflyma, Hyrimoz	2	5

Vedolizumab IV Entyvio IV

Section 100

Item	Formulation	Qty	Rpts
Initial (doses 1, 2 and 3), change or recommencementInitial: online or written. Balance: online or telephone
	PUBLIC vedolizumab 300mg vial	1	2
	PRIVATE vedolizumab 300mg vial	1	2
Initial (dose 4)Online or telephone
	PUBLIC vedolizumab 300mg vial	1	0
	PRIVATE vedolizumab 300mg vial	1	0
ContinuingContinuing: online or written. Balance: online or telephone
	PUBLIC vedolizumab 300mg vial	1	2
	PRIVATE vedolizumab 300mg vial	1	2

Vedolizumab subcutaneous Entyvio SC

Section 85

Item	Formulation	Qty	Rpts
Initial treatment after 3 or 4 doses of IVOnline or written
	vedolizumab 108mg/0.68mL, 2 x 0.68mL pen	2	0
Initial treatment after 2 doses of IVOnline or written
	vedolizumab 108mg/0.68mL, 2 x 0.68mL pen	2	2
Continuing, or switching from IV to subcutaneousOnline or written
	vedolizumab 108mg/0.68mL, 2 x 0.68mL pen	2	5
Balance of supplyOnline or telephone
	vedolizumab 108mg/0.68mL, 2 x 0.68mL pen	2	X

Ustekinumab IV Stelara IV, Steqeyma IV

Section 100

Item	Formulation	Qty	Rpts
Loading (initial, change or recommencement)Initial: online or written. Balance: online or telephone
	PUBLIC ustekinumab 130mg vial	4	0
	PRIVATE ustekinumab 130mg vial	4	0

Ustekinumab subcutaneous Stelara SC, Steqeyma SC

Section 85

Item	Formulation	Qty	Rpts
BalanceOnline or telephone
	ustekinumab 45mg vialStelara SC	2	0
	ustekinumab 45mg syringeSteqeyma SC	2	0
	ustekinumab 90mg syringeSteqeyma SC	1	0
First and subsequent continuingContinuing: online or written. Balance: online or telephone
	ustekinumab 45mg vialStelara SC	2	1 (90mg/12wks) or 2 (90mg/8wks)
	ustekinumab 45mg syringeSteqeyma SC	2	1 (90mg/12wks) or 2 (90mg/8wks)
	ustekinumab 90mg syringeSteqeyma SC	1	1 (90mg/12wks) or 2 (90mg/8wks)
Subsequent continuing for biosimilarsStreamlined authority
	ustekinumab 45mg syringeSteqeyma	2	2
	ustekinumab 90mg syringeSteqeyma	1	2

Upadacitinib Rinvoq

Section 85

Item	Formulation	Qty	Rpts
Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone
	upadacitinib 45mg tabs	28	2
ExtendedOnline or telephone
	upadacitinib 30mg tabs	28	2
Continuing and balanceContinuing: online or written. Balance: online or telephone
	upadacitinib 15mg tabs	28	5
	upadacitinib 30mg tabs	28	5

Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis

Section 100

Item	Formulation	Qty	Rpts
Initial, change or recommencementOnline or written
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
First continuingOnline or written
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
Subsequent continuingOnline or written
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
Balance of supply, all treatment phasesOnline or telephone
	PUBLIC infliximab 100mg vial
	PRIVATE infliximab 100mg vial
Subsequent continuing for biosimilarsStreamlined authority
	PUBLIC infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima	up to 5	2
	PRIVATE infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima	up to 5	2

Infliximab subcutaneous Remsima

Section 85

Item	Formulation	Qty	Rpts
Initial or change (with 2 IV doses) or recommencement (with 1 IV dose)Online or written
	infliximab 120mg/mL subcutaneous syringe	2	2
	infliximab 120mg/mL subcutaneous pen	2	2
Balance of supply, initialOnline or telephone
	infliximab 120mg/mL subcutaneous syringe	2	up to 2
	infliximab 120mg/mL subcutaneous pen	2	up to 2
Continuing, or switching from IV to subcutaneousStreamlined authority
	infliximab 120mg/mL subcutaneous syringe	2	5
	infliximab 120mg/mL subcutaneous pen	2	5

Fistulising Crohn's disease

Fistulising Crohn's disease code sheet, November 2025

Adalimumab Humira, Abrilada, Amgevita, Hadlima, Hyrimoz, Yuflyma

Section 85

Item	Formulation	Qty	Rpts
Loading (initial, change or recommencement)Online or written
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	6 (3 packs of 2)	0
	adalimumab 80mg/0.8mL syringeHumira, Yuflyma, Hyrimoz (pen only)	3	0
	adalimumab 80mg/0.8mL penHumira, Yuflyma, Hyrimoz (pen only)	3	0
BalanceOnline or telephone
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	2	2
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	2	2
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	2	2
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	2	2
First and subsequent continuingContinuing: online or written. Balance: online or telephone
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	2 (40mg/fortnight, NO INC)	5
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	2 (40mg/fortnight, NO INC)	5
	adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz	2 (40mg/fortnight, NO INC)	5
	adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz	2 (40mg/fortnight, NO INC)	5
Subsequent continuing for biosimilarsStreamlined authority
	adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz	2	5
	adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz	2	5
	adalimumab 40mg/0.4mL syringeHadlima, Yuflyma, Hyrimoz	2	5
	adalimumab 40mg/0.4mL penHadlima, Yuflyma, Hyrimoz	2	5

Ustekinumab IV Stelara IV, Steqeyma IV

Section 100

Item	Formulation	Qty	Rpts
Loading (initial, change or recommencement)Initial: online or written. Balance: online or telephone
	PUBLIC ustekinumab 130mg vial	4	0
	PRIVATE ustekinumab 130mg vial	4	0

Ustekinumab subcutaneous Stelara SC, Steqeyma SC

Section 85

Item	Formulation	Qty	Rpts
BalanceOnline or telephone
	ustekinumab 90mg syringe	1	0
First and subsequent continuingOnline or written
	ustekinumab 90mg syringe	1	1 (90mg/12wks) or 2 (90mg/8wks)
Subsequent continuing for biosimilarsStreamlined authority
	ustekinumab 90mg syringeSteqeyma	1	1

Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis

Section 100

Item	Formulation	Qty	Rpts
Initial, change or recommencementOnline or written
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
First continuingOnline or written
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
Subsequent continuingOnline or written
	PUBLIC infliximab 100mg vial	X*	2
	PRIVATE infliximab 100mg vial	X*	2
Balance, all phasesOnline or telephone
	PUBLIC infliximab 100mg vial
	PRIVATE infliximab 100mg vial
Subsequent continuing for biosimilarsStreamlined authority
	PUBLIC infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima	up to 5	2
	PRIVATE infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima	up to 5	2

Infliximab subcutaneous Remsima

Section 85. For patients 18 years and over only.

Item	Formulation	Qty	Rpts
Initial or change (with 2 IV doses) or recommencement (with 1 IV dose)Online or written
	infliximab 120mg/mL syringe, subcutaneous	2	2
	infliximab 120mg/mL pen, subcutaneous	2	2
Balance of supply, including switching formulationOnline or telephone
	infliximab 120mg/mL syringe, subcutaneous	2	up to 2
	infliximab 120mg/mL pen, subcutaneous	2	up to 2
Continuing, or switching from IV to subcutaneousStreamlined authority
	infliximab 120mg/mL syringe, subcutaneous	2	5
	infliximab 120mg/mL pen, subcutaneous	2	5

Notes

X: the maximum quantity or number of repeats is specified within the restriction criteria.
For streamlined authority items, approval must be sought from Services Australia for quantities or repeats greater than the listed values, if permitted.
PUBLIC and PRIVATE refer to the hospital setting in which the infusion is supplied.